BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM
$799M
This Quarter Return
+0.74%
1 Year Return
+36.47%
3 Year Return
+278.05%
5 Year Return
+363.53%
10 Year Return
–
AUM
$895M
AUM Growth
+$895M
(+6.8%)
Cap. Flow
+$105M
Cap. Flow
% of AUM
11.73%
Top 10 Holdings %
Top 10 Hldgs %
69.58%
Holding
37
New
4
Increased
7
Reduced
3
Closed
4
Top Buys
| 1 |
NewAmsterdam Pharma
NAMS
|
$90.5M |
| 2 |
Natera
NTRA
|
$56.2M |
| 3 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$22.7M |
| 4 |
Annexon
ANNX
|
$6.64M |
| 5 |
X4 Pharmaceuticals
XFOR
|
$5.77M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.35% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $126M | 14.04% | 4,831,307 | – | – |
|
2
Nuvalent
NUVL
$5.52B
| $107M | 11.9% | 3,577,267 +149,253 | +4% | +$4.44M |
|
|
3
NewAmsterdam Pharma
NAMS
$2.71B
| $90.5M | 10.11% | +8,300,000 | New | +$90.5M |
|
|
4
Natera
NTRA
$23.1B
| $56.2M | 6.28% | +1,400,000 | New | +$56.2M |
|
5
Mersana Therapeutics
MRSN
$36.5M
| $50.8M | 5.67% | 8,663,673 | – | – |
|
6
Arcutis Biotherapeutics
ARQT
$1.86B
| $44.4M | 4.96% | 3,000,000 | – | – |
|
7
Crinetics Pharmaceuticals
CRNX
$2.92B
| $42.2M | 4.72% | 2,305,558 | – | – |
|
8
Dynavax Technologies
DVAX
$1.19B
| $41.7M | 4.66% | 3,915,000 -1,500,000 | -28% | -$16M |
|
9
Pharvaris
PHVS
$1.39B
| $35.8M | 4% | 3,180,601 | – | – |
|
|
TVRD
10
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $29M | 3.24% | 2,696,030 +48,557 | +2% | +$521K |
|
11
Protagonist Therapeutics
PTGX
$3.67B
| $25.8M | 2.88% | 2,364,410 +103,838 | +5% | +$1.13M |
|
|
12
Annexon
ANNX
$226M
| $25.3M | 2.82% | 4,886,616 +1,284,690 | +36% | +$6.64M |
|
|
EQRX
13
DELISTED
EQRx, Inc. Common Stock
EQRX
| $24.6M | 2.75% | 10,003,573 | – | – |
|
|
CTIC
14
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $22.7M | 2.54% | +3,777,308 | New | +$22.7M |
|
15
Nurix Therapeutics
NRIX
$714M
| $20M | 2.24% | 1,822,883 | – | – |
|
16
Savara
SVRA
$567M
| $18M | 2.01% | 11,622,598 | – | – |
|
17
Solid Biosciences
SLDB
$427M
| $16.8M | 1.88% | 3,130,422 -4,799,496 | -61% | -$25.8M |
|
18
Tango Therapeutics
TNGX
$747M
| $13.9M | 1.56% | 1,921,790 | – | – |
|
|
TSVT
19
DELISTED
2seventy bio
TSVT
| $13.2M | 1.48% | 1,408,901 | – | – |
|
|
20
X4 Pharmaceuticals
XFOR
$84.3M
| $12.1M | 1.35% | 12,202,510 +5,813,074 | +91% | +$5.77M |
|
21
Atea Pharmaceuticals
AVIR
$267M
| $12M | 1.34% | 2,485,638 | – | – |
|
22
Acadia Pharmaceuticals
ACAD
$4.38B
| $11.2M | 1.25% | 701,402 +90,879 | +15% | +$1.45M |
|
23
C4 Therapeutics
CCCC
$185M
| $9.69M | 1.08% | 1,642,210 | – | – |
|
24
Rapid Micro Biosystems
RPID
$107M
| $9.53M | 1.07% | 8,434,560 | – | – |
|
|
SYRS
25
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $7.63M | 0.85% | 2,124,694 +1,042,290 | +96% | +$3.74M |
|